1. Real world adverse events of interspinous spacers using Manufacturer and User Facility Device Experience data
- Author
-
Aggarwal, Nitish and Chow, Robert
- Subjects
Spinal Pain ,medicine.medical_specialty ,Less invasive ,Neurogenic claudication ,law.invention ,Food and drug administration ,03 medical and health sciences ,0302 clinical medicine ,Lumbar ,Randomized controlled trial ,Clinical Research ,law ,Medicine ,User Facility ,Compression fracture ,Adverse effect ,Disproportionality analysis ,030222 orthopedics ,Interspinous spacer ,Interventional ,Veriflex ,X-Stop ,business.industry ,MAUDE database ,Lumbar spinal stenosis ,General Medicine ,medicine.disease ,Coflex ,Physical therapy ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
Background: Lumbar spinal stenosis is a condition of progressive neurogenic claudication that can be managed with lumbar decompression surgery or less invasive interspinous process devices after failed conservative therapy. Popular interspinous process spacers include X-Stop, Vertiflex and Coflex, with X-Stop being taken off market due to its adverse events profile. Methods: A disproportionality analysis was conducted to determine whether a statistically significant signal exists in the three interspinous spacers and the reported adverse events using the Manufacturer and User Facility Device Experience (MAUDE) database maintained by the US Food and Drug Administration. Results: Statistically significant signals were found with each of the three interspinous spacer devices (Coflex, Vertiflex, and X-Stop) and each of the following adverse events: fracture, migration, and pain/worsening symptoms. Conclusions: Further studies such as randomized controlled trials are needed to validate the findings.
- Published
- 2021